Introduction
============

The benefits from the IABP therapy, is due to the support of the coronary flow \[[@B1],[@B2]\] and the reduction of the left ventricular load \[[@B3]\]. This reflects in the improvement of the oxygen supply to demand balance, aiming to reduce the size of the ischemic zone and maintain myocardial viability. This outcome leads to transient support of the left ventricular function in cases of failure during an ischemic insult. However, the effectiveness of the IABP depends on the time elapsed since the onset of the myocardial infarction, as well as on the functional stage of the left ventricle. The frequency of IABP use appears to be increasing as the proportion of high-risk patients for cardiac surgery is increasing and the complication rate is dramatically fallen to an overall rate of 6.5% and a rate of major complications requiring surgery or transfusion of 2.1% \[[@B4]\].

And although historically, higher complication rates have dissuaded clinicians from using it, increasing experience with favorable results during its earlier use, broadens the indications of IABP counterpulsation.

The scope of this report is to elude on to the "traditional & extended" indications of its use.

Unstable angina not responding to medication (4% of the cases)
--------------------------------------------------------------

Although the majority of publications are not randomized studies, they still indicate that patients not responding to the maximum medical treatment can undergo surgery with stabilization through IABP with a low surgical mortality rate and low perioperative myocardial infarction rate \[[@B5],[@B6]\].

Gold and associates \[[@B7]\] showed that the use of the intra-aortic pump eliminates the pain, improves the ST-segment elevation and prevents ventricular tachyarrhythmia. The same group showed that \[[@B8]\] when the IABP support, is followed by a CABG, then the outcome is statistically much better. Roberts et al. \[[@B9]\] agree that in unstable patients with a left ventricular dysfunction, the use of the IABP allows the safe conduct of diagnostic studies with a subsequent surgical treatment with a lower mortality.

Langou et al. \[[@B10]\] in 75 cases of patients where IABP was used noted a surgical mortality of 5.3% and perioperative infarction rate of 6.6%. On the contrary, a study in 55 patients with a similar presentation, operated without IABP, 14.5% died during the operation and 29% suffered a perioperative infarction.

Supporting IABP therapy after a myocardial infarction (24.5% of the cases)
--------------------------------------------------------------------------

Theoretically, IABP could be used during an acute infarction in order to reduce the size and extent of the infarct, support the heart function and reduce the complications related to the incidence. The effects of IABP in 26 patients with heart failure (following an MI), were reviewed by O'Rourke et al. In the first group (n = 12 patients) ischemic pain was observed and a balloon was inserted. The second group (n = 14 patients) did not present persistent ischemic pain and the balloon was skipped. The effect on the ischemic pain was impressive: the pain stopped within a few minutes for 11 patients and within a few hours for one more patient. Out of the 14 patients in-group II, 8 in-hospital deaths occurred.

The same group of researchers \[[@B11]\] in a randomized clinical study, after reviewing the effect of the balloon in heart failure following a myocardial infarction, proved that there is no beneficial effect on the defined end points (morbidity, mortality). It is now accepted that in patients with acute infarction no IABP therapy is given, only as a supportive means followed by myocardial revascularization, when a cardiogenic revascularization when cardiogenic shock or any other mechanical complication that follows an infarction occurs. Since reasons for revascularization are present, the IABP method may be useful in reducing the size of the infarction and the surgical mortality \[[@B12]\].

In patients with acute myocardial infarction DeWood et al. \[[@B13]\] reported the outcomes on 40 patients who received an IABP therapy for cardiogenic shock after an infarction. Group I received IABP therapy and Group II IABP and aortocoronary bypass. Hospital mortality rates in Groups I and II were 71% and 47% respectively. The part of Group II that underwent therapy within 16 hours after the occurrence of the symptoms had lower mortality rate (25%) than that of Group II that underwent operation later than 18 hours after the symptoms were manifested (71%). Patients with acute refraction (coronary dissection or refraction due to plaque fissuring) of a minor branch of the left coronary artery due to percutaneous intervention would benefit from the IABP insertion followed by urgent revascularization \[[@B14]\]. Placement of an IABP in patients following myocardial infarction was most frequently indicated for cardiogenic shock (27.3%), hemodynamic support during catheterization and/or angioplasty (27.2%) or prior to high-risk surgery (11.2%), mechanical complications of acute MI (11.7%), and refractory post-myocardial infarction unstable angina (10.0%) \[[@B15]\].

Supporting with IABP during the percutaneous coronary intervention (10.5% of the cases)
---------------------------------------------------------------------------------------

The effect of the IABP use during coronary catheterization is reported by Adams et al. \[[@B16]\] to be 1 in 1000.

However with the advent of PCI to include multivessel angioplasty, several authorities \[[@B17]\] have adopted the "stand-by" policy during the angioplasty in high risk patients; furthermore Balloon therapy may be the most effective treatment in the first minutes following a complicated angioplasty and as per Ferguson et al. \[[@B18]\] the results from the benchmark registry suggested that the most frequent indications for use of IABP was to provide hemodynamic support during or after cardiac catheterization (20.6%).

IABP in persistent ventricular fibrillation (4.5% of the cases)
---------------------------------------------------------------

Almost all ventricular dysrhytmias attributed to ischemia can temporarily be controlled with medication, so only a few patients would need IABP insertion prior to a revascularization intervention. In patients with acute ischemia, when the ventricular fibrillation resists the ant-fibrillation treatment of second or third line, IABP \[[@B19]\] therapy shall be initiated and immediately after that shall follow heart catheterization and reperfusion treatment.

Patients with ventricular aneurysms and fibrillations with three-vessel disease where CABG is possible have shown good survival outcomes. However, fibrillation has remained in 30% of the cases \[[@B20]\], except if the aneurysm undergoes some type of surgery \[[@B21],[@B22]\].

IABP in "high risk cases" to support low cardiac output syndrome of patients undergoing cardiac surgery
-------------------------------------------------------------------------------------------------------

In the early 70's Berger et al. \[[@B23]\] and Goldman et al. \[[@B24]\] realized that a major indication for the IABP use is cardiac dysfunction after a cardiac intervention. They consider the possibility of urgent use of IABP after cardiac intervention, when all reasons of incomplete reperfusion have been eliminated and weaning from the cardiopulmonary device is difficult, with hypotension and low heart index despite the increased requirements of inotropic support.

In 2001, the Benchmark registry \[[@B18]\] shows that the IABP was used preoperatively in 13% of high-risk patients. It was then became apparent that firstly the definition of "high-risk" patient is somehow arbitrary and secondly that it is possible that preoperative IABP insertion in high-risk patients undergoing CABG may decrease mortality \[[@B25]\]. In a very important report from the Benchmark registry \[[@B26]\] the decision of instituting IABP, were compared between US and non-US centres: a larger percentage of US patients were identified as \'early\' pre-operative support for high-risk CABG\' (15.9% vs 6.6%). A smaller percentage of US patient's vs non-US patients were identified as \'weaning from cardiopulmonary bypass\' (14.3% vs 28.2%). In hospital mortality was lower at US vs non US sites (20.1% vs 28.7%; P \< 0.001). In comparison to Benchmark, IABP at the Australian practise \[[@B27]\] demonstrated a prejudice toward intraoperative use (34.2% versus 16.6%; P \< or = 0.0001) and an aversion to catheter laboratory support (10.6% versus 19%; P \< or = 0.0001). Their outcomes demonstrate comparable mortality (22% versus 20,8; P = ns). As per Dyub et al. \[[@B28]\] a systematic review and meta-analysis compared a total of 1034 patients received preoperative IABP and 1329 did not receive preoperative IABP. The pooled odds ratio (OR) for hospital mortality in patients treated with preoperative IABP was 0.41 (95% CI, 0.21-0.82, p = 0.01). Preoperative IABP was associated with 3.6% absolute risk reduction in mortality and a 59% reduction in the odds for mortality in high-risk patients undergoing CABG. The evidence supports the use of preoperative IABP in high-risk patients to reduce hospital mortality. Miceli et al. \[[@B29]\] clearly underlying that there is no accepted consensus on the definition of high-risk patients who may benefit from the early use of intraaortic balloon pump (IABP) in coronary artery bypass grafting (CABG). They contacted an analysis in a population of 9000 patients in order to identify high-risk groups that they would potentially benefit from early IABP support. They showed that age greater than 70 years, moderate and poor left ventricular dysfunction, previous cardiac surgery, emergency operation, left main disease, Canadian Cardiovascular Society 3--4 class, and recent myocardial infarction were independent risk factors for the need of IABP insertion.

Unfortunately, the definition of high-risk population is lacking consistency in the literature and this in tern creates a bias when it comes to the criticism of all the relevant trials. Christenson and colleagues \[[@B4]\] defined high-risk patients as those full filling at least two of the following criteria: medically refractory unstable angina, ejection fraction less than 0.40, left main stenosis greater than 70%, and redo operation.

Another limitation of relevant reports is the lack of distinction between therapeutic for preoperative cardiogenic shock and prophylactic preoperative IABP insertion. Excluding patients receiving preoperative IABP for hemodynamic instability, shock, recent MI within 3 days, and emergency operation, Holmann and colleagues \[[@B30]\] found no survival advantage for use of prophylactic IABP in hemodynamically stable high-risk patients, although they showed a shorter hospital length of stay. Contrary to this a recently published propensity matched study by Lorusso et al. \[[@B31]\] in high-risk patients (defined as a EuroScore \> 8) did in fact demonstrate a mortality benefit associated with preoperative prophylactic IABP insertion.

Mechanical complications due to acute myocardial infarction (1.2%)
------------------------------------------------------------------

a\) IABP support for acute ischemic mitral failure: Very often it involves the posterior papillary muscle, while the coronary artery responsible by 80% is the right artery. According to Wei et al., mean survival \[[@B32]\] without therapy is three days.

Support with IABP, surgery of the mitral valve and concomitant CABG improves survival rates \[[@B33]\].

b\) IABP support for acute ischemic ventricular septal defect**:** In the majority of cases, cardiogenic shock with pulmonary congestion ensues. According to Logue et al. \[[@B34]\], the deterioration of the patient's clinical condition depends on the extent of involvement of the right ventricle. IABP support during the ischemic ventricular septal defect increases the mean aortic pressure and the cardiac performance and reduces the right ventricular and pulmonary wedge pressure \[[@B35]\].

IABP as a bridge to heart transplantation / refractory ventricular failure (7% of the cases)
--------------------------------------------------------------------------------------------

Therapy with IABP reduces the meta-load improving in this way the performance of the failed heart; up to 22% of the candidates for heart transplantation \[[@B36]\], may require support with IABP as a bridge to transplantation.

Conclusion
==========

Traditionally the indications for using IABP are unstable refractory angina (4%); Supporting IABP therapy after a myocardial infarction (24.5% of the cases); catheter laboratory support (10.5%); ischemia related to intractable ventricular arrhythmias (4.5%); preoperative support (14%); weaning from cardiopulmonary bypass (34%); mechanical complications due to acute myocardial infarction (1.2%); refractory ventricular failure (7%); and other (0.3%).

The increasing early use and effectiveness of the IABP is justified and reflects the number of patients weaned successfully from the device. The success rates are higher in the high-risk groups, when the device was placed early. Therefore, beyond the traditional indications we have adopted a policy of a routine "prophylactic" preoperatively support with IABP in all patients with low ejection fraction.

However, only a prospective, randomized study in high-risk patients will really evaluate the potential merits of such a strategy.
